IgG4 (EP138) Rabbit Monoclonal Primary Antibody

IgG4-related sclerosing disease has been recognized as a systemic disease entity characterized by an elevated serum IgG4 level, sclerosing fibrosis, and diffuse lymphoplasmacytic infiltration with the presence of many IgG4-positive plasma cells. Clinical manifestations are apparent in the pancreas, bile duct, gall bladder, lacrimal gland, salivary gland, retroperitoneum, kidney, lung, breast, thyroid, and prostate. Immunohistochemical analyses in the case of IgG4-related sclerosing disease not only exhibit significantly more than normal IgG4-positive plasma cells in affected tissues but also significantly higher IgG4/IgG ratios (typically > 30%).^1-8

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

IgG4 Positive Control Slides, Product No. 367S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany